Ifosfamide plus oral etoposide salvage chemotherapy for platinum- resistant paclitaxel-pretreated ovarian cancer
dc.contributor.author | Aravantinos, Gerasimos | en |
dc.contributor.author | Dimopoulos, M. A. | en |
dc.contributor.author | Kosmidis, Paraskevas A. | en |
dc.contributor.author | Bafaloukos, Dimitrios | en |
dc.contributor.author | Papadimitriou, C. | en |
dc.contributor.author | Kiamouris, Ch | en |
dc.contributor.author | Pavlidis, Nicholas | en |
dc.contributor.author | Sikiotis, K. | en |
dc.contributor.author | Papakostas, P. | en |
dc.contributor.author | Skarlos, Dimosthenis V. | en |
dc.creator | Aravantinos, Gerasimos | en |
dc.creator | Dimopoulos, M. A. | en |
dc.creator | Kosmidis, Paraskevas A. | en |
dc.creator | Bafaloukos, Dimitrios | en |
dc.creator | Papadimitriou, C. | en |
dc.creator | Kiamouris, Ch | en |
dc.creator | Pavlidis, Nicholas | en |
dc.creator | Sikiotis, K. | en |
dc.creator | Papakostas, P. | en |
dc.creator | Skarlos, Dimosthenis V. | en |
dc.date.accessioned | 2018-06-22T09:52:30Z | |
dc.date.available | 2018-06-22T09:52:30Z | |
dc.date.issued | 2000 | |
dc.identifier.uri | https://gnosis.library.ucy.ac.cy/handle/7/41383 | |
dc.description.abstract | Background: The prognosis of platinum resistant ovarian cancer is very poor and the treatment of choice has not been clearly defined. Patients and methods: We conducted a phase II study with the combination of ifosfamide i.v. at 2.25 g/m2 (days 1, 2) and etoposide per os at 100 mg daily (days 1- 10) every four weeks. To be eligible for the study patients had to be resistant to platinum and paclitaxel pretreated. Results: Forty-one patients entered the study. The median interval from the previous chemotherapy was 3.9 months. The median number of previous chemotherapeutic regimens was 2. Severe toxicities included neutropenia (41% of patients), leukopenia (29%) and thrombocytopenia (13%). Thirty-five patients are assessable for response. Nine patients responded (22% of the eligible, 26% of the assessable), four of them demonstrated complete response to chemotherapy (10% and 12%, respectively), while three patients demonstrated stabilization of their progressive disease. After a median follow-up of 18 months, time to progression is 3 months (range 0.9-14.4), duration of response is 9 months (2.5-11) and median survival is 13 months (2.5-37.4+). Conclusions: The combination of ifosfamide with oral etoposide appears to have significant but manageable toxicity and encouraging efficacy in platinum resistant ovarian cancer. | en |
dc.language.iso | eng | en |
dc.source | Annals of Oncology | en |
dc.subject | Administration | en |
dc.subject | Article | en |
dc.subject | Antineoplastic agents | en |
dc.subject | Human | en |
dc.subject | Humans | en |
dc.subject | Adult | en |
dc.subject | Aged | en |
dc.subject | Female | en |
dc.subject | Middle aged | en |
dc.subject | Cancer combination chemotherapy | en |
dc.subject | Cancer growth | en |
dc.subject | Cancer survival | en |
dc.subject | Chemotherapy | en |
dc.subject | Disease progression | en |
dc.subject | Neoplasm | en |
dc.subject | Ovarian cancer | en |
dc.subject | Ovarian neoplasms | en |
dc.subject | Ovary cancer | en |
dc.subject | Paclitaxel | en |
dc.subject | Priority journal | en |
dc.subject | Alopecia | en |
dc.subject | Antineoplastic combined chemotherapy protocols | en |
dc.subject | Clinical article | en |
dc.subject | Clinical trial | en |
dc.subject | Drug efficacy | en |
dc.subject | Drug resistance | en |
dc.subject | Leukopenia | en |
dc.subject | Neurotoxicity | en |
dc.subject | Neutropenia | en |
dc.subject | Phase 2 clinical trial | en |
dc.subject | Phytogenic | en |
dc.subject | Allergy | en |
dc.subject | Antineoplastic activity | en |
dc.subject | Combination | en |
dc.subject | Etoposide | en |
dc.subject | Human tissue | en |
dc.subject | Ifosfamide | en |
dc.subject | Infusions | en |
dc.subject | Intravenous | en |
dc.subject | Nephrotoxicity | en |
dc.subject | Oral | en |
dc.subject | Platinum | en |
dc.subject | Prognosis | en |
dc.subject | Salvage therapy | en |
dc.subject | Survival analysis | en |
dc.title | Ifosfamide plus oral etoposide salvage chemotherapy for platinum- resistant paclitaxel-pretreated ovarian cancer | en |
dc.type | info:eu-repo/semantics/article | |
dc.identifier.doi | 10.1023/A:1008327412571 | |
dc.description.volume | 11 | |
dc.description.issue | 5 | |
dc.description.startingpage | 607 | |
dc.description.endingpage | 612 | |
dc.author.faculty | Ιατρική Σχολή / Medical School | |
dc.author.department | Ιατρική Σχολή / Medical School | |
dc.type.uhtype | Article | en |
dc.contributor.orcid | Pavlidis, Nicholas [0000-0002-2195-9961] | |
dc.contributor.orcid | Aravantinos, Gerasimos [0000-0002-2106-1713] | |
dc.gnosis.orcid | 0000-0002-2195-9961 | |
dc.gnosis.orcid | 0000-0002-2106-1713 |
Files in this item
Files | Size | Format | View |
---|---|---|---|
There are no files associated with this item. |